Diabetes mellitus, bone mineral density, and fracture risk

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 14, Issue 6, 2007, Pages 429-435

  Strotmeyer, Elsa S ^a   Cauley, Jane A ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Bone mineral density; Fracture; Osteoporosis; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Indexed keywords

GLITAZONE DERIVATIVE;

ARTICLE; BONE DENSITY; DIABETES MELLITUS; FRACTURE; GLUCOSE BLOOD LEVEL; HIP; HUMAN; HUMERUS; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; RISK ASSESSMENT; RISK FACTOR; VERTEBRA;

BONE DENSITY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; FRACTURES, BONE; HUMANS; MALE; RISK ASSESSMENT; RISK FACTORS;

EID: 35848959474     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3282f1cba3     Document Type: Article

References (38)

1. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis. Osteoporos Int 2007; 18:427-444. A meta-analysis of fracture risk at the hip for type 1 diabetes, fracture risk at multiple sites for type 2 diabetes, and spine and hip BMD for both type 1 and type 2 diabetes.
2. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of Type 1 and Type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007; 166:495-505. A meta-analysis of hip fracture risk in type 1 and type 2 diabetes with restricted meta-analysis in type 2 diabetes for major confounders or mediators.
3. Ahmed LA, Joakimsen RM, Berntsen GK, et al. Diabetes mellitus and the risk of nonvertebral fractures: the Tromso study. Osteoporos Int 2006; 17:495-500. Large population-based study in Norway of nonvertebral and hip fracture incidence in type 1 and type 2 diabetic men and women with stratified analyses by insulin use in type 2 diabetic adults.
4. Janghorbani M, Feskanich D, Willett WC, Hu F. Prospective study of diabetes and risk of hip fracture: The Nurses Health Study. Diabetes Care 2006; 29:1573-1578. Large study of nurses in the USA of higher hip-fracture incidence in type 1 and type 2 diabetic women with stratified analyses by insulin use, disease duration, and obesity in type 2 diabetic women.
5. Holmberg AH, Johnell O, Nilsson PM, et al. Risk factors for fragility fracture in middle age. A prospective population-based study of 33,000 men and women. Osteoporos Int 2006; 17:1065-1077. A population-based study in Sweden of diabetes (not stratified by type) at multiple sites and higher risk for any fracture and hip fracture in middle-aged diabetic men and women, although there was higher risk for vertebral and foot fracture in diabetic women only.
6. Lipscombe LL, Jamal SA, Booth GL, Hawker GA. The risk of hip fractures in older individuals with diabetes: a population-based study. Diabetes Care 2007; 30:835-841. The largest study of diabetes (not stratified by type) and higher hip fracture incidence to-date in men and women from Ontario, Canada, showing equivalent risk in diabetic men and women.
7. Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 2006; 91:3404-3410. A large multiethnic study in the USA of type 2 diabetes and fracture incidence at multiple sites with higher risk of any fracture, hip, spine and foot fractures; and the first report of higher incidence for any fracture in black diabetic women.
8. Schwartz A, Sellmeyer D, Ensrud K, et al., for the Study of Osteoporotic Fractures Research Group. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 2001; 86:32-38.
9. Strotmeyer ES, Cauley JA, Schwartz AV, et al., for the Health ABC Study. Nontraumatic fracture risk with diabetes and impaired fasting glucose in older white and black adults: The Health, Aging and Body Composition Study. Arch Intern Med 2005; 165:1612-1617.
10. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427-2443. The first published report of a two-fold higher fracture rate in women randomized to rosiglitazone compared to women randomized to metformin or glyburide.
11. Food and Drug Administration. 2007 Safety alerts for drugs, biologics, medical devices, and dietary supplements. www.fda.gov/medwatch/safety/2007/ safety07.htm. 2007. The Food and Drug Administration Safety Alert on higher fracture risk in women using Actos (pioglitazone) tablets, ACTOplus met (pioglitazone and metformin hydrochloride) tablets, and Duetact (pioglitazone and glimepiride) tablets.
12. Strotmeyer ES, Schwartz AV, Newman AB. Thiazolidinediones and the risk of nontraumatic fractures in patients with diabetes: in reply. Arch Intern Med 2006; 166:1043.
13. Strotmeyer ES, Cauley JA, Orchard TJ, et al. Middle-aged premenopausal women with type 1 diabetes have lower bone mineral density and calcaneal quantitative ultrasound than nondiabetic women. Diabetes Care 2006; 29:306-311. A case - control study found that middle-aged women with type 1 diabetes had lower BMD at the hip, femoral neck and whole body, although not at the spine, and lower calcaneal broadband ultrasound attenuation than women without diabetes, after multivariate adjustment.
14. Rakic V, Davis WA, Chubb SA, et al. Bone mineral density and its determinants in diabetes: the Fremantle Diabetes Study. Diabetologia 2006; 49:863-871.
15. Miazgowski T, Pynka S, Noworyta-Zietara M, et al. Bone mineral density and hip structural analysis in type 1 diabetic men. Eur J Endocrinol 2007; 156:123-127. A case - control study found middle-aged men with type 1 diabetes had a lower spine BMD than age-, weight-, and height-matched control men, although no difference in hip BMD or hip strength.
16. Hadjidakis DJ, Raptis AE, Sfakianakis M, et al. Bone mineral density of both genders in Type 1 diabetes according to bone composition. J Diabetes Complications 2006; 20:302-307. A case - control study matched on age, sex and BMI found that young type 1 diabetic men had a lower spine BMD and femoral neck BMD and young type 1 diabetic women had a lower femoral neck BMD.
17. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Min Res 2005; 20:1185-1194.
18. Bechtold S, Dirlenbach I, Raile K, et al. Early manifestation of type 1 diabetes in children is a risk factor for changed bone geometry: data using peripheral quantitative computed tomography. Pediatrics 2006; 118:e627-e634. Prepubertal type 1 diabetic children were more likely to have higher trabecular BMD, lower cortical BMD, and lower total and cortical cross-sectional area compared to a reference population.
19. Strotmeyer ES, Cauley JA, Schwartz AV, et al. Diabetes is associated independently of body composition with bone mineral density and bone volume in older white and black men and women: the Health, Aging, and Body Composition Study. J Bone Miner Res 2004; 19:1084-1091.
20. Schwartz AV, Sellmeyer DE, Strotmeyer ES, et al. Diabetes and bone loss at the hip in older black and white adults. J Bone Min Res 2005; 20:596-603.
21. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91:3349-3354. Older type 2 diabetic white women using TZD showed greater BMD loss at multiple sites although there were no differences in men or black women.
22. Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 2007; 30:1574-1576. Older type 2 diabetic men using TZD showed greater BMD loss at the hip, femoral neck, and spine without multivariate adjustments.
23. Grey A, Bolland M, Gamble G, et al. The peroxisome-proliferator- activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007; 92:1305-1310. A trial of nondiabetic postmenopausal women without osteoporosis found those randomized to rosiglitazone after 14 weeks of treatment had significantly greater hip BMD loss compared to a placebo group.
24. •] reviews current data on TZD use, bone density and fractures.
25. ••] reviews the relationship of bone density and fractures with type 2 diabetes and TZD use.
26. Alexopoulou O, Jamart J, Devogelaer JP, et al. Bone density and markers of bone remodeling in type 1 male diabetic patients. Diabetes Metab 2006; 32:453-458.
27. Tamura T, Yoneda M, Yamane K, et al. Serum leptin and adiponectin are positively associated with bone mineral density at the distal radius in patients with type 2 diabetes mellitus. Metabolism 2007; 56:623-628.
28. Dobnig H, Piswanger-Solkner JC, Roth M, et al. Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. J Clin Endocrin Metab 2006; 91:3355-3363.
29. Schwartz A. Diabetes mellitus: does it affect bone? Calcif Tissue Int 2003; 73:515-519.
30. He H, Liu R, Desta T, et al. Diabetes causes decreased osteoclastogenesis, reduced bone formation, and enhanced apoptosis of osteoblastic cells in bacteria stimulated bone loss. Endocrinol 2004; 145:447-452.
31. Liu Z, Aronson J, Wahl EC, et al. A novel rat model for the study of deficits in bone formation in type-2 diabetes. Acta Orthop 2007; 78:46-55. Zucker diabetic fatty rats (a model of type 2 diabetes) may be useful to study diabetes and bone formation in vivo.
32. Zhang S-Q, Chen G-H, Lu W-L, et al. Effects on the bones of vanadyl acetylacetonate by oral administration: a comparison study in diabetic rats. J Bone Miner Metab 2007; 25:293-301. The db/db diabetic mouse model may be useful to study diabetes and bone formation in vivo.
33. Karaguzel G, Akcurin S, Ozdem S, et al. Bone mineral density and alterations of bone metabolism in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol 2006; 19:805-814.
34. Hein G, Weiss C, Lehmann G, et al. Advanced glycation end product modification of bone proteins and bone remodelling: hypothesis and preliminary immunohistochemical findings. Ann Rheum Dis 2006; 65:101-104. A study showing an inverse association between AGE staining intensity and percentage of osteoporotic bone surface covered by osteoblasts.
35. Strotmeyer ES, Cauley JA, Schwartz AV, et al., for the Health ABC Study. Reduced peripheral nerve function is related to lower hip BMD and calcaneal QUS in older white and black adults: The Health, Aging and Body Composition Study. J Bone Min Res 2006; 21:1803-1810. This cross-sectional study showed an association of poorer peripheral nerve function and lower BMD in a dose - response relationship for older men and women.
36. Farhat GN, Strotmeyer ES, Newman AB, et al., for the Health ABC Study. Volumetric and areal bone mineral density measures are associated with cardiovascular disease in older men and women: The Health, Aging and Body Composition Study (Health ABC). Calcif Tissue Int 2006; 79:102-111. This cross-sectional study showed an association of cardiovascular disease and lower BMD in a dose - response relationship for older men and women.
37. Fried LF, Shlipak MG, Stehman-Breen C, et al. Kidney function predicts the rate of bone loss in older individuals: The Cardiovascular Health Study. J Gerontol A Biol Sci Med Sci 2006; 61A:743-748. This prospective study found an association of poorer renal function and greater BMD loss at the hip in a dose - response relationship for older men and women.
38. Ensrud KE, Lui LY, Taylor BC, et al., Osteoporotic Fractures Research Group. Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 2007; 167:133-139. This case - cohort study found an association of poorer renal function and higher hip fracture risk in a dose - response relationship for older women.